# Canakinumab MAP in COVID-19 Pneumonia With CRS

> **NCT04476706** · — · NO_LONGER_AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Cytokine Release Syndrome in COVID-19-induced Pneumonia

## Interventions

- **DRUG:** canakinumab

## Key facts

- **NCT ID:** NCT04476706
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** NO_LONGER_AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476706, "Canakinumab MAP in COVID-19 Pneumonia With CRS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04476706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*